abc27

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin ...
Naija Gist - Latest

NAFDAC Warns Against Fake Oxytocin Drugs; Here’s How to Stay Safe

NAFDAC warns Nigerians against fake oxytocin injections linked to life-threatening risks for mothers and babies. Here’s all you need to know. On September 1st, the National Agency for Food and Drug ...

Peptonic Medical AB

Peptonic Medical AB company and executive profile by Barron's. View the latest PMED company infomation and executive bios.
Mena FN

Tonix Pharmaceuticals Announces First Patient Dosed In The Investigator-Initiated FOCUS Study Of Tonix's Intranasal Potentiated Oxytocin In AVP-D Conducted By Massachusetts ...

(MENAFN- GlobeNewsWire - Nasdaq) FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients ...
Yahoo Finance

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts ...

CHATHAM, N.J., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated biotechnology company with marketed products and a ...
Finanznachrichten

Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin ...